The federal government charged the three generic drugs manufacturer with violating the False Claims Act, the Sherman Antitrust Act, and the Anti-Kickback Statute.
Settlement Agreement with Taro Pharmaceuticals USA, Sandoz, and Apotex
Taro Pharmaceuticals USA signed a settlement agreement with the United States government through the Justice Department on September 30, 2021.
Under the settlement agreement, the New York-based generics drug manufacturer agreed to pay $213.2 million.
Taro Pharmaceuticals USA also executed a Deferred Prosecution Agreement (DPA) with the DOJ’s Antitrust Division in connection with the two-count Criminal Information filed against it.
Sandoz signed a settlement agreement with the United States through the DOJ on September 28. The generics drugs manufacturer also executed a DPA with the department’s Antitrust Division.
Under the settlement agreement, Sandoz will pay $185 million to resolve the four-count Criminal Information filed against it.
Meanwhile, Apotex entered into a settlement agreement September 30, 2021. The Florida-based generic drugs manufacturer agreed to pay $49 million to resolve the one-count Criminal Information filed against it.
